Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)
Summary: Background: Little is known about how demographic, behavioural, and vaccine-related factors affect risk of post-vaccination SARS-CoV-2 infection. We aimed to identify risk factors for SARS-CoV-2 infection after primary and booster vaccinations. Methods: This prospective, population-based,...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-11-01
|
| Series: | The Lancet Regional Health. Europe |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666776222001971 |
| _version_ | 1818058492323299328 |
|---|---|
| author | Giulia Vivaldi David A. Jolliffe Hayley Holt Florence Tydeman Mohammad Talaei Gwyneth A. Davies Ronan A. Lyons Christopher J. Griffiths Frank Kee Aziz Sheikh Seif O. Shaheen Adrian R. Martineau |
| author_facet | Giulia Vivaldi David A. Jolliffe Hayley Holt Florence Tydeman Mohammad Talaei Gwyneth A. Davies Ronan A. Lyons Christopher J. Griffiths Frank Kee Aziz Sheikh Seif O. Shaheen Adrian R. Martineau |
| author_sort | Giulia Vivaldi |
| collection | DOAJ |
| description | Summary: Background: Little is known about how demographic, behavioural, and vaccine-related factors affect risk of post-vaccination SARS-CoV-2 infection. We aimed to identify risk factors for SARS-CoV-2 infection after primary and booster vaccinations. Methods: This prospective, population-based, UK study in adults (≥16 years) vaccinated against SARS-CoV-2 assessed risk of breakthrough SARS-CoV-2 infection up to February, 2022, for participants who completed a primary vaccination course (ChAdOx1 nCoV-19 or BNT162b2) and those who received a booster dose (BNT162b2 or mRNA-1273). Cox regression models explored associations between sociodemographic, behavioural, clinical, pharmacological, and nutritional factors and test-positive breakthrough infection, adjusted for local weekly SARS-CoV-2 incidence. Findings: 1051 (7·1%) of 14 713 post-primary participants and 1009 (9·5%) of 10 665 post-booster participants reported breakthrough infection, over a median follow-up of 203 days (IQR 195–216) and 85 days (66–103), respectively. Primary vaccination with ChAdOx1 (vs BNT162b2) was associated with higher risk of infection in both post-primary analysis (adjusted hazard ratio 1·63, 95% CI 1·41–1·88) and after an mRNA-1273 booster (1·26 [1·00–1·57] vs BNT162b2 primary and booster). Lower risk of infection was associated with older age (post-primary: 0·97 [0·96–0·97] per year; post-booster: 0·97 [0·97–0·98]), whereas higher risk of infection was associated with lower educational attainment (post-primary: 1·78 [1·44–2·20] for primary/secondary vs postgraduate; post-booster: 1·46 [1·16–1·83]) and at least three weekly visits to indoor public places (post-primary: 1·36 [1·13–1·63] vs none; post-booster: 1·29 [1·07–1·56]). Interpretation: Vaccine type, socioeconomic status, age, and behaviours affect risk of breakthrough infection after primary and booster vaccinations. Funding: Barts Charity, UK Research and Innovation Industrial Strategy Challenge Fund. |
| first_indexed | 2024-12-10T13:01:29Z |
| format | Article |
| id | doaj.art-0ba04dd374404b5295f2d985a99d0f28 |
| institution | Directory Open Access Journal |
| issn | 2666-7762 |
| language | English |
| last_indexed | 2024-12-10T13:01:29Z |
| publishDate | 2022-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Lancet Regional Health. Europe |
| spelling | doaj.art-0ba04dd374404b5295f2d985a99d0f282022-12-22T01:47:57ZengElsevierThe Lancet Regional Health. Europe2666-77622022-11-0122100501Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)Giulia Vivaldi0David A. Jolliffe1Hayley Holt2Florence Tydeman3Mohammad Talaei4Gwyneth A. Davies5Ronan A. Lyons6Christopher J. Griffiths7Frank Kee8Aziz Sheikh9Seif O. Shaheen10Adrian R. Martineau11Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Corresponding authors at: Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, London E1 2AT, UK.Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UKBlizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Asthma UK Centre for Applied Research, Queen Mary University of London, London, UKBlizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UKWolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UKPopulation Data Science, Swansea University Medical School, Singleton Park, Swansea, UKPopulation Data Science, Swansea University Medical School, Singleton Park, Swansea, UKWolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Asthma UK Centre for Applied Research, Queen Mary University of London, London, UKCentre for Public Health Research (NI), Queen's University Belfast, Belfast, UKUsher Institute, University of Edinburgh, Edinburgh, UKWolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UKBlizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Asthma UK Centre for Applied Research, Queen Mary University of London, London, UK; Corresponding authors at: Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, London E1 2AT, UK.Summary: Background: Little is known about how demographic, behavioural, and vaccine-related factors affect risk of post-vaccination SARS-CoV-2 infection. We aimed to identify risk factors for SARS-CoV-2 infection after primary and booster vaccinations. Methods: This prospective, population-based, UK study in adults (≥16 years) vaccinated against SARS-CoV-2 assessed risk of breakthrough SARS-CoV-2 infection up to February, 2022, for participants who completed a primary vaccination course (ChAdOx1 nCoV-19 or BNT162b2) and those who received a booster dose (BNT162b2 or mRNA-1273). Cox regression models explored associations between sociodemographic, behavioural, clinical, pharmacological, and nutritional factors and test-positive breakthrough infection, adjusted for local weekly SARS-CoV-2 incidence. Findings: 1051 (7·1%) of 14 713 post-primary participants and 1009 (9·5%) of 10 665 post-booster participants reported breakthrough infection, over a median follow-up of 203 days (IQR 195–216) and 85 days (66–103), respectively. Primary vaccination with ChAdOx1 (vs BNT162b2) was associated with higher risk of infection in both post-primary analysis (adjusted hazard ratio 1·63, 95% CI 1·41–1·88) and after an mRNA-1273 booster (1·26 [1·00–1·57] vs BNT162b2 primary and booster). Lower risk of infection was associated with older age (post-primary: 0·97 [0·96–0·97] per year; post-booster: 0·97 [0·97–0·98]), whereas higher risk of infection was associated with lower educational attainment (post-primary: 1·78 [1·44–2·20] for primary/secondary vs postgraduate; post-booster: 1·46 [1·16–1·83]) and at least three weekly visits to indoor public places (post-primary: 1·36 [1·13–1·63] vs none; post-booster: 1·29 [1·07–1·56]). Interpretation: Vaccine type, socioeconomic status, age, and behaviours affect risk of breakthrough infection after primary and booster vaccinations. Funding: Barts Charity, UK Research and Innovation Industrial Strategy Challenge Fund.http://www.sciencedirect.com/science/article/pii/S2666776222001971SARS-CoV-2VaccinationBreakthrough infectionChAdOx1BNT162b2mRNA-1273 |
| spellingShingle | Giulia Vivaldi David A. Jolliffe Hayley Holt Florence Tydeman Mohammad Talaei Gwyneth A. Davies Ronan A. Lyons Christopher J. Griffiths Frank Kee Aziz Sheikh Seif O. Shaheen Adrian R. Martineau Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK) The Lancet Regional Health. Europe SARS-CoV-2 Vaccination Breakthrough infection ChAdOx1 BNT162b2 mRNA-1273 |
| title | Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK) |
| title_full | Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK) |
| title_fullStr | Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK) |
| title_full_unstemmed | Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK) |
| title_short | Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK) |
| title_sort | risk factors for sars cov 2 infection after primary vaccination with chadox1 ncov 19 or bnt162b2 and after booster vaccination with bnt162b2 or mrna 1273 a population based cohort study covidence uk |
| topic | SARS-CoV-2 Vaccination Breakthrough infection ChAdOx1 BNT162b2 mRNA-1273 |
| url | http://www.sciencedirect.com/science/article/pii/S2666776222001971 |
| work_keys_str_mv | AT giuliavivaldi riskfactorsforsarscov2infectionafterprimaryvaccinationwithchadox1ncov19orbnt162b2andafterboostervaccinationwithbnt162b2ormrna1273apopulationbasedcohortstudycovidenceuk AT davidajolliffe riskfactorsforsarscov2infectionafterprimaryvaccinationwithchadox1ncov19orbnt162b2andafterboostervaccinationwithbnt162b2ormrna1273apopulationbasedcohortstudycovidenceuk AT hayleyholt riskfactorsforsarscov2infectionafterprimaryvaccinationwithchadox1ncov19orbnt162b2andafterboostervaccinationwithbnt162b2ormrna1273apopulationbasedcohortstudycovidenceuk AT florencetydeman riskfactorsforsarscov2infectionafterprimaryvaccinationwithchadox1ncov19orbnt162b2andafterboostervaccinationwithbnt162b2ormrna1273apopulationbasedcohortstudycovidenceuk AT mohammadtalaei riskfactorsforsarscov2infectionafterprimaryvaccinationwithchadox1ncov19orbnt162b2andafterboostervaccinationwithbnt162b2ormrna1273apopulationbasedcohortstudycovidenceuk AT gwynethadavies riskfactorsforsarscov2infectionafterprimaryvaccinationwithchadox1ncov19orbnt162b2andafterboostervaccinationwithbnt162b2ormrna1273apopulationbasedcohortstudycovidenceuk AT ronanalyons riskfactorsforsarscov2infectionafterprimaryvaccinationwithchadox1ncov19orbnt162b2andafterboostervaccinationwithbnt162b2ormrna1273apopulationbasedcohortstudycovidenceuk AT christopherjgriffiths riskfactorsforsarscov2infectionafterprimaryvaccinationwithchadox1ncov19orbnt162b2andafterboostervaccinationwithbnt162b2ormrna1273apopulationbasedcohortstudycovidenceuk AT frankkee riskfactorsforsarscov2infectionafterprimaryvaccinationwithchadox1ncov19orbnt162b2andafterboostervaccinationwithbnt162b2ormrna1273apopulationbasedcohortstudycovidenceuk AT azizsheikh riskfactorsforsarscov2infectionafterprimaryvaccinationwithchadox1ncov19orbnt162b2andafterboostervaccinationwithbnt162b2ormrna1273apopulationbasedcohortstudycovidenceuk AT seifoshaheen riskfactorsforsarscov2infectionafterprimaryvaccinationwithchadox1ncov19orbnt162b2andafterboostervaccinationwithbnt162b2ormrna1273apopulationbasedcohortstudycovidenceuk AT adrianrmartineau riskfactorsforsarscov2infectionafterprimaryvaccinationwithchadox1ncov19orbnt162b2andafterboostervaccinationwithbnt162b2ormrna1273apopulationbasedcohortstudycovidenceuk |